Event review: The Future of QA/QC for Complex Biologics
Posted: 22 December 2021 | European Pharmaceutical Review | No comments yet
On 30 November and 1 December 2021, European Pharmaceutical Review hosted its first ever event – The Future of QA/QC for Complex Biologics Online Summit. Bringing together more than 600 attendees, 15 expert speakers and Thermo Fisher Scientific and Merck as sponsors, the summit gave industry experts the chance to advance their QA/QC skills to ensure they can meet the challenges of advanced therapy medicinal products and other emerging biologic therapies.
WITH NEARLY 100 cell and gene therapies launched in markets worldwide and hundreds more under development, as well as novel vaccine technologies paving our way out of the COVID-19 pandemic, it has never been more essential for QA/QC professionals to rise to the challenge of complex biological therapies.
As biologics increase in complexity, gain precision, become personalised and more widely adopted globally, patient safety and product quality are only growing in importance.
At this event, experts from across the biopharmaceutical industry gave the audience the skills and information they need to release high quality biological therapies ranging from vaccines to antibodies and cell & gene therapies, while enhancing efficiency, productivity and cost-effectiveness.
Didn’t have a chance to join the live event? Not to worry, you can access the sessions on-demand here.
Issue
Related topics
Analytical techniques, Biologics, Biopharmaceuticals, Drug Safety, Environmental Monitoring, Gene therapy, Impurities, Industry Insight, Informatics, Lab Automation, Liquid Chromatography - Mass Spectrometry (LC-MS), Mass Spectrometry, Material Identification, Microbiology, Proteins, QA/QC, Regenerative Medicine, Regulation & Legislation, Technology, Therapeutics, Vaccines
